NOTHE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Kazuma TOMIZUKA, et al.

Title:

METHOD FOR MODIFYING

**CHROMOSOMES** 

Appl. No.:

09/763,362

SEP 1 4 2006

Filing Date:

4/23/2001

Examiner:


Thaian N. Ton

Art Unit:

1632

Confn No.:

4670



# SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

09/18/2006 RMEBRAHT 00000008 09763362

01 FC:1806

180.00 OP

### **TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(d), before payment of the issue fee.

## **RELEVANCE OF EACH DOCUMENT**

All of the documents are in English.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

#### **STATEMENT**

The undersigned hereby states in accordance with 37 CFR §1.704(d) that each item of information contained in the information disclosure statement was first cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR §1.56(c) more than thirty days prior to the filing of the information disclosure statement.

#### **FEE**

A credit card payment form in the amount of \$180.00 is enclosed in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(d) in the amount of \$180.00.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment form being unsigned, providing incorrect information resulting in a

Stephen A. Bent, Reg. No. 29,768

Vid Mohan-Ram, Reg. No. 55,459

rejected credit card transaction, or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date September 14,2005 By 1.5.

FOLEY & LARDNER LLP

Washington Harbour

3000 K Street NW, Suite 500

Washington, D.C. 20007-5143

Telephone:

(202) 672-5404

Facsimile:

(202) 672-5399

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTSEP 14 2006

Filing Date

4/23/2001

Date Submitted: September 14,2006

(use as many sheets as necessary in page 14,23/2007

Sheet 2 of 2 Attorney Docket Number 081356-0158

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		BUETOW; et al.; Genome Maps V; Science, New Series, Vol. 265, No. 5181, Genome Issue; Sept 30, 1994, 2055-2070	
		COLLINS, et al.; A High-Density YAC Contig Map of Human Chromosome 22; <i>Nature</i> , Vol. 377; Supp. Sept. 28, 1995; 367-379	
		KUROIWA, et al.; Efficient Modification of a Human Chromosome By Telomere-Directed Truncation in High Homologous Recombination-Proficient Chicken DT40 Cells; <i>Nucleic Acids Research</i> , 1998, Vol. 26, No. 47; 3447-3448	
		WEICHHOLD, et al; The CD8a Locus Is Located on the Telomere Side of the Immunoglobulin K Locus at a Distance of 2Mb; <i>Genomics 16</i> ; 1993; 512-514	
			-

Examiner	Date Considered
Signature	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.